Wyeth has signed an alliance with UK's Biotica Technology Ltd that could earn the privately held biotech firm up to $195 million, if new medicines are successfully brought to market.
Biotica, which was spun out of Cambridge University, has granted Wyeth worldwide rights to its most advanced drug candidates, as well as access to the technology to discover new compounds.
Biotica uses biosynthetic engineering to create compounds that are not easily made using conventional synthetic chemistry, including new versions of rapamycin, which forms the basis of several immunosuppressant, anti-infective and experimental cancer drugs.
Reuters
No comments:
Post a Comment